People taking oral oncolytic therapy tended to receive improved quality of care when clinicians used a standardized tool to measure symptom burden in a study involving more than 1,200 individuals.

8 oncology practices used a modified version of the Edmonton Symptom Assessment Scale prior to each outpatient visit in participants who were prescribed oral oncolytic therapy. They categorized 13 symptoms as mild, moderate, or severe.

83% of symptoms were mild, 12% moderate, and the remainder severe.